Literature DB >> 2372496

The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.

J A Goldberg1, D J Kerr, D G Watson, N Willmott, C D Bates, J H McKillop, C S McArdle.   

Abstract

The pharmacokinetics of 5-fluorouracil (5FU) following its administration via the hepatic artery in conjunction with biodegradable albumin microspheres and angiotensin II have been studied. Peripheral venous concentrations of 5FU are lower and plasma clearance values higher following intrahepatic arterial administration compared with a similar dose administered by intravenous infusion over both 2 h and 24 h. For the 2 h drug infusions, plasma 5FU concentrations following co-treatment with angiotensin II and microspheres via the hepatic artery were intermediate between those of arterial and venous infusions of 5FU alone. There was a trend towards the peak plasma drug concentrations and the area under the plasma concentration-time curve (AUC) being significantly lower following co-treatment with angiotensin II and microspheres compared with intra-arterial and intravenous infusions of 5FU over 24 h. Co-administration of 5FU, angiotensin II and microspheres via the hepatic artery may reduce drug exposure in the systemic compartment and therefore may increase the therapeutic ratio of 5FU administration via the hepatic artery.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2372496      PMCID: PMC1971687          DOI: 10.1038/bjc.1990.204

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  Intra-arterial hepatic chemotherapy for liver malignancy.

Authors:  S T Malik; P F Wrigley
Journal:  BMJ       Date:  1988-08-13

2.  Comparison of liquid- and gas-liquid chromatographic assays of 5-fluorouracil in plasma.

Authors:  N Christophidis; G Mihaly; F Vajda; W Louis
Journal:  Clin Chem       Date:  1979-01       Impact factor: 8.327

3.  Serum albumin beads: an injectable, biodegradable system for the sustained release of drugs.

Authors:  T K Lee; T D Sokoloski; G P Royer
Journal:  Science       Date:  1981-07-10       Impact factor: 47.728

4.  Changes in distribution of hepatic blood flow induced by intra-arterial infusion of angiotensin II in human hepatic cancer.

Authors:  Y Sasaki; S Imaoka; Y Hasegawa; S Nakano; O Ishikawa; H Ohigashi; K Taniguchi; H Koyama; T Iwanaga; T Terasawa
Journal:  Cancer       Date:  1985-01-15       Impact factor: 6.860

5.  Arteriovenous shunting of microspheres in patients with colorectal liver metastases: errors in assessment due to free pertechnetate, and the effect of angiotensin II.

Authors:  J A Goldberg; M S Bradnam; D J Kerr; D M Haughton; J H McKillop; R G Bessent; N Willmott; C S McArdle; W D George
Journal:  Nucl Med Commun       Date:  1987-12       Impact factor: 1.690

6.  Single photon emission computed tomographic studies (SPECT) of hepatic arterial perfusion scintigraphy (HAPS) in patients with colorectal liver metastases: improved tumour targetting by microspheres with angiotensin II.

Authors:  J A Goldberg; M S Bradnam; D J Kerr; J H McKillop; R G Bessent; C S McArdle; N Willmott; W D George
Journal:  Nucl Med Commun       Date:  1987-12       Impact factor: 1.690

7.  Adriamycin-loaded albumin microspheres: preparation, in vivo distribution and release in the rat.

Authors:  N Willmott; J Cummings; J F Stuart; A T Florence
Journal:  Biopharm Drug Dispos       Date:  1985 Jan-Mar       Impact factor: 1.627

8.  Improved regional selectivity of hepatic arterial mitomycin by starch microspheres.

Authors:  J W Gyves; W D Ensminger; D VanHarken; J Niederhuber; P Stetson; S Walker
Journal:  Clin Pharmacol Ther       Date:  1983-08       Impact factor: 6.875

9.  Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.

Authors:  J A Goldberg; D J Kerr; N Willmott; J H McKillop; C S McArdle
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

  9 in total
  8 in total

Review 1.  Can pharmacokinetic monitoring improve clinical use of fluorouracil?

Authors:  A M Young; S Daryanani; D J Kerr
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 2.  5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.

Authors:  J L Grem
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

3.  Relationships between body composition parameters and fluorouracil pharmacokinetics.

Authors:  Milena Gusella; Sivia Toso; Eros Ferrazzi; Mariano Ferrari; Roberto Padrini
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 4.  Clinical pharmacokinetic advantages of new drug delivery methods for the treatment of liver tumours.

Authors:  J H Anderson; H W Warren; C S McArdle
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

5.  Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma.

Authors:  Koji Uchino; Shuntaro Obi; Ryosuke Tateishi; Shinpei Sato; Miho Kanda; Takahisa Sato; Toru Arano; Kenichiro Enooku; Eriko Goto; Ryota Masuzaki; Hayato Nakagawa; Yoshinari Asaoka; Yuji Kondo; Noriyo Yamashiki; Tadashi Goto; Shuichiro Shiina; Masao Omata; Haruhiko Yoshida; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2012-03-22       Impact factor: 6.772

6.  A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastases.

Authors:  J H Anderson; D J Kerr; T G Cooke; C S McArdle
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

7.  A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid.

Authors:  J H Anderson; D J Kerr; A Setanoians; T G Cooke; C S McArdle
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

8.  A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases.

Authors:  H W Warren; J H Anderson; P O'Gorman; E Kane; D J Kerr; T G Cooke; C S McArdle
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.